All In Biotech

NDA 212832 · Fresenius Kabi USA

Potassium Phosphates

Potassium Phosphate, Dibasic, Potassium Phosphate, Monobasic · Intravenous

Priority review

Last checked: Nov 19, 2026Latest source record: Aug 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Nov 26, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

49

8 Phase 3, 5 recruiting

FAERS reports

886

765 serious, 174 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 10, 2026.

Potassium Phosphates Injection is indicated as a source of phosphorus: • in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. • for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. Potassium Phosphates Injection is a phosphorus replacement product indicated as a source of phosphorus: • in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. ( 1 ) • for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. ( 1 )

Mechanism: Phosphorus in the form of organic and inorganic phosphate has a variety of biochemical functions in all organs and tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis and bone mineralization.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 26, 2019 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
5 products under this application
  • POTASSIUM PHOSPHATES · POTASSIUM PHOSPHATE, DIBASIC 1.18GM/5ML (236MG/ML); POTASSIUM PHOSPHATE, MONOBASIC 1.12GM/5ML (224MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE · POTASSIUM PHOSPHATE, DIBASIC 1.18GM/100ML (11.8MG/ML); POTASSIUM PHOSPHATE, MONOBASIC 1.12GM/100ML (11.2MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • POTASSIUM PHOSPHATES · POTASSIUM PHOSPHATE, DIBASIC 3.54GM/15ML (236MG/ML); POTASSIUM PHOSPHATE, MONOBASIC 3.36GM/15ML (224MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE · POTASSIUM PHOSPHATE, DIBASIC 1.18GM/250ML (4.72MG/ML); POTASSIUM PHOSPHATE, MONOBASIC 1.12GM/250ML (4.48MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • POTASSIUM PHOSPHATES · POTASSIUM PHOSPHATE, DIBASIC 11.8GM/50ML (236MG/ML); POTASSIUM PHOSPHATE, MONOBASIC 11.2GM/50ML (224MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Potassium Phosphates" as an intervention, any sponsor and status, largest first.

All 49 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea64
  • nausea62
  • pyrexia61
  • pneumonia59
  • cytokine release syndrome52
  • off label use52
  • vomiting49
  • hypotension47
  • dyspnoea44
  • acute kidney injury42
  • fatigue42
  • febrile neutropenia42

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200418
200511
200623
200721
200812
200931
201028
201137
201237
201327
201436
201546
201645
201731
201832
201947
202076
202179
202275
202362
202434
202540
202638

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Fresenius Kabi USA · Also marketed as Potassium Phosphates In 0.9% Sodium Chloride

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.